CD274 and neoplasm: In order to achieve optimal efficacy, the concurrent administration of immune checkpoint inhibitors (e.g. PD-1/PD-L1 or CTLA-4 antibodies) can disrupt the state of immune tolerance within the tumor immune microenvironment.